An observational study in Glaucoma, sponsored by University of Maryland, Baltimore. Recruiting at 1 site in United States. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-08-10.
Sponsored by University of Maryland, Baltimore · Observational
Among 490 studies in Glaucoma with a site in United States — 77 open to participants now, 96 under way, 5 of them phase 3. Glaucoma · United States.
Among the 490 studies in Glaucoma with a site in United States, this one is the 72nd largest by planned enrollment of the 110 observational ones that give a count, is one of 29 that started in 2025, is one of 110 observational ones, reaches primary completion later than 38 of the 95 other live ones, and was the 445th registered.
1,419 studies on the registry are indexed under Glaucoma; 223 are open to participants now.
Browse Glaucoma studies →77 of the 490 studies in Glaucoma with a site in United States are open now. Recruiting first, the newest first:
Duke University · Sites in United States
Tavo Biotherapeutics · Sites in United States
Astellas Pharma Global Development, Inc. · Sites in United States
Brett King · Sites in United States
Tomey Corporation · Sites in United States
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 156 Glaucoma studies recruiting now, 114 (73%) set no upper age limit and 9 (6%) stop at 75 or younger; 13 take children under 18; 45 take healthy volunteers.
This study: 18 Years and older · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
490 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 34 · Phase 2 88 · Phase 3 51 · Phase 4 66
First in 1976; this study’s year is marked. 29 started in 2025.
This study's planned enrollment of 60 is below the median of 101 across 385 observational studies indexed under Glaucoma.
Median enrollment 79 across the 364 interventional studies, 100 across the 110 observational. Of the 356 that completed or were terminated, 138 (39%) have results posted.
This tab as a report to print or save as PDF → With an account.
210 of 490 have an industry lead sponsor. The 10 most frequent:
University of Maryland, Baltimore is the lead sponsor of 700 studies on the registry; 132 are open to participants now.
Of its 92 completed or terminated interventional studies of FDA-regulated products, 66 (72%) have results posted.
University of Maryland, Baltimore has 3 studies filed under Glaucoma — fewer than ten, so there is no comparison to draw.
35 of the studies in Glaucoma with a site in United States that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT04967989Phase 3University of PittsburghClarifying the Optimal Application of SLT Therapy Trial | 2027-06-30 |
| NCT07510087Marc Toeteberg-HarmsGlaucoma Related Quality of Life | 2026-11-30 |
| NCT05626426Stanford UniversityElectrical Stimulation for the Treatment of Optic Neuropathies | 2026-12 |
| NCT05626491Stanford UniversityElectrical Stimulation for the Treatment of Glaucoma | 2026-12 |
| NCT06615661Iantrek, Inc.A Real-World Evidence Study of Goniotomy With the C-REX™ Instrument in Patients With Primary Open Angle Glaucoma | 2026-12 |
Among the 490 studies in Glaucoma with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This pilot study evaluates the biomechanical properties of the cornea in glaucoma patients using Brillouin microscopy, a non-contact imaging technique. The study aims to compare corneal stiffness between patients with normal-tension glaucoma, high-tension glaucoma, and healthy controls, and to assess changes in corneal biomechanics following intraocular pressure (IOP)-lowering treatment. The goal is to determine whether Brillouin-derived biomechanical measurements can serve as biomarkers for glaucoma risk and progression.
This study explores the biomechanical properties of the cornea in patients with glaucoma using a novel, non-contact imaging technique called Brillouin microscopy. The technology allows in vivo assessment of tissue stiffness without physical perturbation, potentially offering new insights into glaucoma risk and response to therapy.
The study includes two parts: a cross-sectional comparison between patients with normal- and high-tension glaucoma and healthy controls, and a longitudinal analysis of biomechanical changes following IOP-lowering treatment with either prostaglandin analogs or beta blockers.
The goal is to determine whether corneal biomechanics can serve as a biomarker for glaucoma susceptibility and progression, and to evaluate the feasibility of integrating Brillouin imaging into clinical glaucoma care.
The study population includes adults aged 18 years and older with newly diagnosed, treatment-naïve primary open angle glaucoma (POAG), including both normal tension glaucoma (NTG) and high tension glaucoma (HTG), as well as age-matched healthy control subjects. Subjects must meet strict ophthalmic inclusion criteria and will be recruited from the University of Maryland Department of Ophthalmology and Visual Sciences and affiliated clinics. Exclusion criteria include significant ocular comorbidities, prior ocular surgery, systemic diseases that affect the eye, or prior glaucoma therapy.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
- Age 18 years or older
Diagnosis of primary open angle glaucoma (POAG) or no history of glaucoma (for controls)
Open angle on gonioscopy (Shaffer grade 3 or 4)
Best-corrected visual acuity of 20/25 or better
Refractive error between +3.00 and -5.00 diopters
No prior use of topical glaucoma medications
Diagnosis of:
High Tension Glaucoma (IOP ≥ 22 mmHg on 3 visits)
Normal Tension Glaucoma (IOP ≤ 21 mmHg on 3 visits)
OR age-matched control with normal optic nerve and visual fields
Exclusion Criteria:
Corneal abnormalities or conditions interfering with Brillouin or applanation tonometry
Retinal diseases affecting RNFL (e.g., macular traction)
History of ocular surgery or laser
Diagnosis of diabetes
History of uveitis
History of prolonged use
Neurodegenerative or systemic diseases (e.g., multiple sclerosis, Alzheimer's, Parkinson's, schizophrenia)
Unreliable visual fields
to beta blockers (e.g., bradycardia, severe pulmonary disease)
Moderate to severe glaucoma (per Hodapp-Anderson-Parrish criteria)
History of contact lens use
Low blood pressure
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Newly diagnosed, treatment-naïve subjects with normal tension glaucoma. Brillouin imaging will be performed at baseline, and in a subset receiving IOP-lowering therapy, additional imaging will be performed at 3 and 6 weeks.
Drug: Prostaglandin Analogue -Containing IOP-Lowering Therapy · Drug: Beta Blocker · Device: Brillouin Microscopy
Newly diagnosed, treatment-naïve subjects with high tension glaucoma. Brillouin imaging will be performed at baseline, and in a subset receiving IOP-lowering therapy, additional imaging will be performed at 3 and 6 weeks.
Drug: Prostaglandin Analogue -Containing IOP-Lowering Therapy · Drug: Beta Blocker · Device: Brillouin Microscopy
Age-matched healthy control subjects with no history of glaucoma or IOP-lowering therapy. Brillouin imaging will be performed at a single time point for cross-sectional comparison.
Device: Brillouin Microscopy
Subjects with glaucoma may be prescribed prostaglandin analogs as part of their clinical care. This group will be observed longitudinally to assess changes in corneal biomechanics.
Also known as: Latanoprost, Travaprost, Bimatoprost
Subjects with glaucoma may be prescribed topical beta blockers as part of their clinical care. This group will be observed longitudinally to assess changes in corneal biomechanics.
Also known as: Timolol
Brillouin microscopy is a non-contact optical imaging method used to assess the biomechanical properties of the cornea in vivo with three-dimensional resolution. It will be used to evaluate corneal stiffness in all study subjects.
Also known as: Brillouin Imaging
Change in Corneal Biomechanical Modulus
Brillouin microscopy will be used to measure the corneal modulus of elasticity. The primary outcome is the change in corneal stiffness (Brillouin shift in MHz) across time points in subjects treated with prostaglandin analogs versus beta blockers, and between groups at baseline (NTG, HTG, controls).
Time frame: Baseline, 3 weeks, and 6 weeks
Plan to share: No — Individual participant data will not be shared. Summary-level results will be published and made publicly available per NIH policy.
No publications or documents are linked to this record.
Started Sep 2025 (actual). Primary completion is estimated for Mar 2027, 18 months after the start.
Of 110 non-industry observational studies under Glaucoma, half reached primary completion within 47 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 208. This study's planned 18 months is below that.
Counting every sponsor, half of 134 studies reached it within 31 months; a quarter within 12 and three quarters within 208.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
University of Maryland, Baltimore →